Moleculin Biotech Files 8-K: Material Agreement & Equity Sales

TL;DR

Moleculin Biotech signed a big deal and sold some stock, filing an 8-K.

AI Summary

Moleculin Biotech, Inc. announced on August 28, 2025, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and provided financial statements and exhibits as part of this 8-K filing.

Why It Matters

This filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.

Risk Assessment

Risk Level: medium — The filing involves a material definitive agreement and unregistered equity sales, which can introduce financial and regulatory risks.

Key Numbers

• 001-37758 — SEC File Number (Identifies the company's filing with the SEC.)
• 47-4671997 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Moleculin Biotech, Inc. (company) — Registrant
• August 28, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Houston, TX (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.37 — common stock with an exercise price of $0.37 per share (the "Existing Warrants"). P
• $6.0 million — e gross proceeds of up to approximately $6.0 million from the exercise of the Existing Warra
• $0.55 — cement Warrant has an exercise price of $0.55 per share, will be exercisable upon the
• $0.11 — ance price, subject to a floor price of $0.11. If at any time on or after the date of
• $6.0 m — ants is expected to total approximately $6.0 million, before deducting financial advis

Filing Documents

• mbrx20250828_8k.htm (8-K) — 39KB
• ex_858061.htm (EX-4.1) — 140KB
• ex_858062.htm (EX-10.1) — 48KB
• ex_857884.htm (EX-99.1) — 11KB
• a01.jpg (GRAPHIC) — 10KB
• 0001437749-25-027975.txt ( ) — 448KB
• mbrx-20250828.xsd (EX-101.SCH) — 3KB
• mbrx-20250828_def.xml (EX-101.DEF) — 12KB
• mbrx-20250828_lab.xml (EX-101.LAB) — 15KB
• mbrx-20250828_pre.xml (EX-101.PRE) — 12KB
• mbrx20250828_8k_htm.xml (XML) — 3KB

01

Item 1.01 Entry into a Material Definitive Agreement On August 27, 2025, Moleculin Biotech, Inc. (the "Company") entered into a warrant exercise inducement offer letter (the "Inducement Letter") with holders of certain existing warrants (the "Holders") to purchase up to 16,216,216 shares of Company common stock with an exercise price of $0.37 per share (the "Existing Warrants"). Pursuant to the Inducement Letter, the Holders agreed to exercise the Existing Warrants, and the Company agreed to issue the Holders new warrants to purchase up to a number of shares of Company common stock equal to 400% of the number of shares of Company common stock underlying the exercised Existing Warrants, comprised of new Series F warrants to purchase up to 64,864,864 shares of Company common stock (the "Inducement Warrants" and the shares of Company common stock underlying the Inducement Warrants, the "Inducement Warrant Shares") with an exercise term of five years from the initial exercise date. The issuance of the shares of Company common stock underlying the Existing Warrants have been registered pursuant to an effective registration statement on Form S-1 (File No. 333-287727). The Company anticipates receiving aggregate gross proceeds of up to approximately $6.0 million from the exercise of the Existing Warrants before deducting fees and other expenses payable by it. Each Inducement Warrant has an exercise price of $0.55 per share, will be exercisable upon the receipt of shareholder approval (the "Shareholder Approval") of the issuance of the Inducement Warrant Shares, and may be exercised for a period of five years from such approval. If while the Inducement Warrants are outstanding, the Company issues or sells, or is deemed to have issued or sold, any common stock and/or common stock equivalents other than in connection with certain exempt issuances, at a purchase price per share less than the exercise price of the Inducement Warrants in effect immediately prior to such is

02

Item 3.02 Unregistered Sales of Equity Securities The Company issued the Inducement Warrants pursuant to the exemption from the registration requirements of the Securities Act available under Section 4(a)(2). Neither the issuance of the Inducement Warrants nor the Inducement Warrant Shares will be registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. The description of the Inducement Warrants under Item 1.01 of this Form 8-K is incorporated by reference herein.

01

Item 7.01 Regulation FD Disclosure On August 28, 2025, Moleculin Biotech, Inc. (the "Company"), issued a press release which announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 16,216,216 shares of common stock of the Company originally issued in June 2025 at an exercise price of $0.37 per share. The shares of common stock issuable upon exercise of the outstanding warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-287727). The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $6.0 million, before deducting financial advisory fees. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 4.1 Form of Inducement Warrant 10.1 Form of Inducement Letter 99.1 Press Release dated August 28, 2025 104 Cover page Interactive Data File (formatted as Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOLECULIN BIOTECH, INC. Date: August 28, 2025 By: /s/ Jonathan P. Foster Jonathan P. Foster

View Full Filing

View this 8-K filing on SEC EDGAR